MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia, Myeloid, Acute
Interventions
Drug: Placebo
Procedure: HSCT
First Posted Date
2018-01-31
Last Posted Date
2023-04-21
Lead Sponsor
Pfizer
Target Recruit Count
730
Registration Number
NCT03416179
Locations
🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

🇵🇱

WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland

and more 146 locations

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

Phase 1
Withdrawn
Conditions
Inflammatory Bowel Disease
Interventions
Biological: PF 06687234
Biological: [124I]IB PF 06687234
First Posted Date
2018-01-30
Last Posted Date
2020-11-03
Lead Sponsor
Pfizer
Registration Number
NCT03414788
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

Phase 4
Completed
Conditions
Onychomycosis
Tinea Unguium
Interventions
First Posted Date
2018-01-23
Last Posted Date
2018-04-17
Lead Sponsor
Pfizer
Target Recruit Count
55
Registration Number
NCT03405818
Locations
🇺🇸

Madera Family Medical Group, Madera, California, United States

🇺🇸

MedStar Health Research Institute - MedStar Georgetown University Hospital, Washington, District of Columbia, United States

🇺🇸

Stanford University School of Medicine, Palo Alto, California, United States

and more 9 locations

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Epoetin Hospira MDV
Drug: Epoetin Hospira SDV
First Posted Date
2018-01-12
Last Posted Date
2018-05-17
Lead Sponsor
Pfizer
Target Recruit Count
68
Registration Number
NCT03398473
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Phase 3
Active, not recruiting
Conditions
mCRPC
Interventions
First Posted Date
2018-01-10
Last Posted Date
2025-06-10
Lead Sponsor
Pfizer
Target Recruit Count
1054
Registration Number
NCT03395197
Locations
🇺🇸

South Jordan Health Center -University of Utah, South Jordan, Utah, United States

🇺🇸

Inova Schar Cancer Institute Infusion Pharmacy, Fairfax, Virginia, United States

🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

and more 316 locations

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Phase 2
Completed
Conditions
Crohn's Disease
Interventions
Drug: PF-06651600 Placebo
First Posted Date
2018-01-10
Last Posted Date
2024-10-30
Lead Sponsor
Pfizer
Target Recruit Count
244
Registration Number
NCT03395184
Locations
🇺🇦

Regional Municipal Non-profit Enterprise "Chernivtsi Regional Clinical Hospital", Surgery Department, Chernivtsi, Ukraine

🇺🇸

Dothan Surgery Center, Dothan, Alabama, United States

🇺🇸

Gut P.C., dba Digestive Health Specialists of the Southeast, Dothan, Alabama, United States

and more 183 locations

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis

Completed
Conditions
Arthritis, Rheumatoid
First Posted Date
2018-01-02
Last Posted Date
2024-10-21
Lead Sponsor
Pfizer
Target Recruit Count
1459
Registration Number
NCT03387423
Locations
🇩🇪

Private Practice Richter, Rostock, Germany

🇩🇪

Private Practice, Templin, Germany

🇩🇪

Private Praxis, Duesseldorf, Nordrhein-westfalen, Germany

and more 84 locations

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2017-12-29
Last Posted Date
2019-10-14
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT03386279
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Safety and Efficacy of Xalkori ROS1

Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2017-12-18
Last Posted Date
2025-02-14
Lead Sponsor
Pfizer
Target Recruit Count
100
Registration Number
NCT03375242
Locations
🇯🇵

Pfizer local country office, Tokyo, Japan

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-06865571 Immediate release suspension
Drug: PF-06865571 Slow release MR tablets
Drug: PF-06865571 Fast release MR tablets
Drug: PF-06865571 Immediate release tablets
First Posted Date
2017-12-13
Last Posted Date
2018-04-17
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT03372044
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy